Cancer immunotherapy: moving beyond current vaccines - Test2 - elhamkhani - TriplyDB

Cancer immunotherapy: moving beyond current vaccines

Cancer immunotherapy: moving beyond current vaccines

http://www.wikidata.org/entity/Q24548229

about

Lectin of Concanavalin A as an anti-hepatoma therapeutic agent Focus on adoptive T cell transfer trials in melanoma Translatability scoring in drug development: eight case studies Research progress on Livin protein: an inhibitor of apoptosis The response of autologous T cells to a human melanoma is dominated by mutated neoantigens Adoptive immunotherapy for cancer: building on success IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Improved endpoints for cancer immunotherapy trials Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity Dendritic cell vaccines for brain tumors Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens Adoptive cell transfer: a clinical path to effective cancer immunotherapy Cancer immunoediting from immune surveillance to immune escape Adoptive T cell therapy for cancer in the clinic A balanced review of the status T cell-based therapy against cancer Adoptive T cell therapy: Addressing challenges in cancer immunotherapy Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma Progress and controversies in developing cancer vaccines.Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency Modelling vaccination schedules for a cancer immunoprevention vaccine.Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.Role of Toll-like receptors in adjuvant-augmented immune therapies.Oncolytic Viruses: Therapeutics With an Identity Crisis Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy Clinical Development of the E75 Vaccine in Breast Cancer Cancer immunotherapy: the beginning of the end of cancer?Vaccine adjuvants as potential cancer immunotherapeutics T cell receptor mimic antibodies for cancer therapy Recent advances in the field of anti-cancer immunotherapy Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy Lymphoma Immunotherapy: Current Status Immunotherapy of Childhood Sarcomas Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.HPV Carcinomas in Immunocompromised Patients Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides Biomimetic and synthetic interfaces to tune immune responses Stem cells and targeted approaches to melanoma cure Pathways and therapeutic targets in melanoma

P2860

Q21284430-77009144-CBE9-4FF5-840A-FF46AC6D8DDD Q21328679-CE56108B-62DE-4904-81BE-CBCD9B065DC3 Q22241760-751C5C1E-C3D6-4549-8519-071B7394A054 Q24304472-C97C34D4-00A0-46DA-A0C3-181F3EBB11A3 Q24535034-5419A3EB-2B72-418F-B595-4A70CFA1D6AA Q24546258-B6A68443-C792-41DB-9D1C-FCD499EA53F2 Q24546362-FA9AB184-F93C-4C4C-BE9E-B5A542CBACC4 Q24596055-599EDB2F-B1FC-4955-82E3-2AD411262C2E Q24603112-0C3CC163-37F8-402B-AC62-935DE5CCFB0C Q24610550-A0B016D7-EF02-4BCD-90B4-14C2A641C75A Q24641823-3D7B9998-32A9-4824-A814-B63762A87E48 Q24644442-7CA32D72-1DD6-4D87-9B2F-86A8A6DC9F03 Q24644774-E9AA5C67-07D6-45D5-B855-68EE15B72F0B Q24655415-081714DA-E107-4039-A6E5-DFE06D32FEC7 Q24680405-E5F0DC5B-25C6-4147-86C4-38646C57A3DC Q24800636-B7C27A64-4684-4E85-9BFA-2E51C4593AA7 Q24805804-F0F0C68A-E5B9-40F0-BF22-45ECE6CDA7C7 Q24808685-3D19F7FE-C242-425A-AA86-472573CBAFD6 Q24810256-3459793D-8AEF-4140-BC21-27D9491C54CB Q24810259-DBF4F2AC-97B5-454E-8F3A-EF1D2EAEAC50 Q24810987-52AFAA53-A433-48C2-A893-46CD869BC0AE Q24813328-3A7A7B54-8E21-4D0C-A5C1-ADA9801A8CCB Q25257661-6B3A88E4-4846-4FE5-AA5F-54646783A29E Q26741020-7515BE02-24A5-4D15-BBD8-D0DA3D15E369 Q26742107-F267CCBE-AE05-4112-9C28-F9110A729850 Q26745440-F874C3BB-DDC9-4BCB-8B34-5CA8A2E831AF Q26752277-EF574864-F08D-44C7-939C-FA1A92F9DC5C Q26752522-D63DD1DF-EE21-427C-835A-6DC54216396C Q26768271-769AD754-7B6C-4280-9F9C-93F73797B96E Q26775602-C2E379B9-CEDA-4514-9FFF-171BC2731E80 Q26782131-77288D09-1840-4331-9D2E-A9B81AD53F0B Q26782566-46E0811F-F4DE-419F-B105-061D4EA345D0 Q26782902-9B5D9FB0-2558-41D1-A8B2-EEF5D80B2D1C Q26795369-2656D759-AFAD-40C2-B0E7-4CC4A210AFA4 Q26796314-E152E448-CCBE-43D2-95A1-C6CF082F3B94 Q26799629-2695565D-4288-4E14-893B-643EA2E4E23B Q26800123-3FF55E1D-5079-464B-9435-DD4D6FB43BEC Q26801229-B57DDF48-FE77-4FFB-9BE6-3BE53B6E0A87 Q26825014-F0D72250-2B9E-426B-B9D0-536FD2DAB76E Q26865736-08D9C97B-60AB-4EFA-A739-50D3919F95C8

P2860

Cancer immunotherapy: moving beyond current vaccines

http://www.wikidata.org/entity/Q24548229

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Cancer immunotherapy: moving beyond current vaccines

@ast

Cancer immunotherapy: moving beyond current vaccines

@en

Cancer immunotherapy: moving beyond current vaccines

@nl

type

label

Cancer immunotherapy: moving beyond current vaccines

@ast

Cancer immunotherapy: moving beyond current vaccines

@en

Cancer immunotherapy: moving beyond current vaccines

@nl

prefLabel

Cancer immunotherapy: moving beyond current vaccines

@ast

Cancer immunotherapy: moving beyond current vaccines

@en

Cancer immunotherapy: moving beyond current vaccines

@nl

P1433

Q24548229-E2E7C8B7-FCA3-4A1F-8F3E-A971CB2BDD58

P1476

Q24548229-702C4DB4-1874-4417-BBB3-B5BD52E60407

P2093

Q24548229-5E4D7E1B-9F88-4425-B07C-2C8027FC2348

Q24548229-DE02D141-5D2E-4134-8ED8-45E7E982338B

P2860

Q24548229-058C4458-6E45-453E-89F9-89DA7C6D0767

Q24548229-0822C0C8-88D3-4142-AE2C-8F7D40D9B072

Q24548229-084EF88A-AE7B-40AF-98A7-9E24E22CD615

Q24548229-12AF90D4-9303-49BF-A55F-83ED9B4569F8

Q24548229-192497AA-F90E-4FF6-8166-99CA759A9E03

Q24548229-19742E71-5531-45CF-8BC5-E43F7B68DD8C

Q24548229-1C6C7381-33CF-4E5C-A881-F74E2D65E472

Q24548229-2297AC36-9679-4745-A446-7C541717D1F5

Q24548229-284790E9-F48E-451E-91C9-14F7B4195D5F

Q24548229-29839EEC-B8D0-452A-BDBC-BEBCE88228DD

P2888

Q24548229-68D71994-BA79-409D-9387-9F73C2330D8E

P304

Q24548229-E1460218-A800-4055-89E5-A8EA758E4667

P31

Q24548229-21135FD0-CFFC-4EEC-9CAD-2A48BA3A59CB

P3181

Q24548229-A102013F-A472-4EA8-809F-9EF0CEA88B11

P356

Q24548229-7C312C2C-3E32-475A-B3BE-AD7C6255EE81

P407

Q24548229-547B6DD6-9993-4FEC-A1AA-AC2859C963BA

P433

Q24548229-23F8A36A-30AE-498E-9E7E-8D80A297AF62

P478

Q24548229-C61F8B26-381C-4FC7-AAB3-F39BF5116121

P50

Q24548229-44AEB24E-24F8-4002-A8BA-70A0614B9B76

P577

Q24548229-3760E2D3-E26A-4501-BC75-65C153304E68

P5875

Q24548229-ED03E345-75C7-477A-B837-A5AA23EA1EF9

P6179

Q24548229-3E1C9253-7CB9-4202-ACC5-A6463701F1C3

P698

Q24548229-415C937D-A731-40B9-BB36-2F7742F5F5BF

P921

Q24548229-E6F58018-E018-42B0-9170-2B6109103C30

P932

Q24548229-A0309327-0DE4-425B-AE50-C020335C3460

P3181

P356

P1433

Nature Medicine

P1476

Cancer immunotherapy: moving beyond current vaccines

@en

P2093

James C Yang

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Toll-like receptors

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Reporting results of cancer treatment

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

P2888

P304

909-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

380095

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NM1100

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8372972

http://www.w3.org/2001/XMLSchema#string

P6179

1001965372

http://www.w3.org/2001/XMLSchema#string

P698

15340416

http://www.w3.org/2001/XMLSchema#string

P921

P932

1435696

http://www.w3.org/2001/XMLSchema#string